Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
22
datasets available to search
ShareScore release 0.9.0
Dataset results
22 results for “Sars-Cov-2; antibody responses”
Pre-vaccination and early B cell signatures of the antibody response to SARS-CoV-2 mRNA vaccine
<p>The data presented in Code repository for Kardava, L., Rachmaninoff, N., Lau, W. W., Buckner, C. M., Trihemasava, K., Blazkova, J., ... & Moir, S. (2022). Early human B cell signatures of the primary antibody response to mRNA vaccination. Proceedings of the National Academy of Sciences, 119(28), e2204607119.<a href="https://www.pnas.org/doi/epdf/10.1073/pnas.2204607119">https://www.pnas.org/doi/epdf/10.1073/pnas.2204607119</a> are made available here.</p> <p>All code to reproduce the figures can be found here: https://github.com/niaid/COVID_Vaccine_Bcells</p> <p><a href="https://zenodo.org/api/files/f93859d0-b062-4def-8b17-c0f21ee36f09/all_subjects_cd19_positive_and_keys.zip">all_subjects_cd19_positive_and_keys.zip</a> contains a CSV file of all CD19+ cells with flowSOM clusters shown. Accompanying files allow for matching of timepoint and subject information.</p> <p><a href="https://zenodo.org/api/files/f93859d0-b062-4def-8b17-c0f21ee36f09/All_subjects_FCS_files_deidentified.zip">All_subjects_FCS_files_deidentified.zip</a> contains the raw fcs files and is organized by timepoint and subject.</p>
Data from: A longitudinal assessment of the antibody response to SARS-CoV-2 infection in the New Mexican population
Open the record for dataset details and reuse information.
Resources of "Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1"
<p>Resources of the article "Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1". See https://github.com/yunlongcaolab/SARS-CoV-2-JN.1-mAbs for future updates.</p>
Code related to article "The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients"
<p>This code is related to article "The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients"</p> <p>Abstract</p> <p>The factors involved in the persistence of antibodies to SARS-CoV-2 are unknown. We evaluated the antibody response to SARS-CoV-2 in personnel from 10 healthcare facilities and its association with individuals’ characteristics and COVID-19 symptoms in an observational study. We enrolled 4735 subjects (corresponding to 80% of all personnel) over a period of 5 months when the spreading of the virus was drastically reduced. For each participant, we determined the rate of antibody increase or decrease over time in relation to 93 features analyzed in univariate and multivariate analyses through a machine learning approach. In individuals positive for IgG ( ≥ 12 AU/mL) at the beginning of th study, we found an increase [p= 0.0002] in antibody response in symptomatic subjects, particularly with anosmia/dysgeusia (OR 2.75, 95% CI 1.753 – 4.301), in a multivariate logistic regression analysis. This may be linked to the persistence of SARS-CoV-2 in the olfactory bulb.</p>
Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19)
ClinicalTrials.gov study NCT04425759. IPD Sharing: NO. Countries: 1. Publications: 0.
The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19
ClinicalTrials.gov study NCT04734886. IPD Sharing: NO. Countries: 1. Publications: 2.
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and tissue-resident T cell response in the lungs and protects hamsters against SARS-CoV-2
GEO Series GSE193288. Mesocricetus auratus. 14 samples. Type: Expression profiling by high throughput sequencing.
Memory B cells dominate the early antibody-secreting cell response to SARS-CoV-2 mRNA vaccination in naïve individuals independently of their antibody affinity
GEO Series GSE244297. Homo sapiens. 24 samples. Type: Expression profiling by high throughput sequencing; Other.
Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses
<p><span>Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by human sera is a strong correlate of protection against symptomatic and severe Coronavirus Disease 2019 (COVID-19). The emergence of antigenically distinct SARS-CoV-2 variants of concern (VOCs) and the relatively rapid waning of serum antibody titers, however, raises questions about the sustainability of serum protection. In addition to serum neutralization, other antibody functionalities and the memory B cell (MBC) response are suggested to help maintaining this protection. In this study, we investigate the breadth of spike (S) protein-specific serum antibodies that mediate effector functions by interacting with Fc-gamma receptor IIa (<span>FcγRIIa) and FcγRIIIa,</span> and of the receptor binding domain (RBD)-specific MBCs, following a primary SARS-CoV-2 infection with the D614G, Alpha, Beta, Gamma, Delta, Omicron BA.1 or BA.2 variant. Irrespectively of the variant causing the infection, the breadth of S protein-specific serum antibodies that interact with <span>FcγRIIa and FcγRIIIa and the RBD-specific MBC responses </span>exceeded the breadth of serum neutralization, although the Alpha-induced B cell response seemed more strain-specific<span>. Between VOC groups, both quantitative and qualitative differences in the immune responses were observed, suggesting differences in immunogenicity. Overall</span>, this study contributes to the understanding of protective humoral and B cell responses in the light of emerging antigenically distinct VOCs, and highlights the need to study the immune system beyond serum neutralization <span>to gain a better understanding of the protection against emerging variants. </span></span></p>
SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia
ClinicalTrials.gov study NCT06435403. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients
ClinicalTrials.gov study NCT04483622. IPD Sharing: NO. Countries: 1. Publications: 0.
Antibody Response and Longevity Post SARS-CoV-2 Vaccine (SARS-AB)
ClinicalTrials.gov study NCT05515081. IPD Sharing: NO. Countries: 1. Publications: 0.
COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses
ClinicalTrials.gov study NCT04483908. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients
ClinicalTrials.gov study NCT04465981. IPD Sharing: NO. Countries: 1. Publications: 0.
The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus
ClinicalTrials.gov study NCT06851611. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within t
ClinicalTrials.gov study NCT04760990. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Booster Effect of mRNA Vaccine on Antibody Response for SARS-CoV-2 After Complete Vaccination With Sinos
ClinicalTrials.gov study NCT05213455. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
SARS-CoV-2 Antibody Response in Children Aged 5-11 Years Following Vaccination Against COVID-19
ClinicalTrials.gov study NCT05175989. IPD Sharing: NO. Countries: 1. Publications: 0.
Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19
ClinicalTrials.gov study NCT04367714. IPD Sharing: NO. Countries: 1. Publications: 0.
Antibody response against Influenza and SARS-CoV-2 antigens
GEO Series GSE295393. Severe acute respiratory syndrome coronavirus 2; Mus musculus; Influenza A virus. 49 samples. Type: Other.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.